Enterococcus faecalis as Next Generation Probiotics
Background E. faecalis and Diseases Products Brochures FAQs Resources
As one of the current most popular therapies, next-generation probiotics (NGPs) are effective at disease prevention and treatment. Creative Biolabs provides a series of Enterococcus faecalis (E. faecalis)-based drug discovery and development services for our clients all over the world. Equipped with a team of professional scientists, we are capable of providing you with a wide spectrum of customized services on E. faecalis studies. We can accommodate the specific properties of your project and provide flexible integrated solutions.
Introduction of E. faecalis
E. faecalis is a gram-positive bacterium that is responsible for many infectious diseases in humans, such as human urinary tract infections. E. faecalis can be found in most parts of the human body, especially in the gastrointestinal tract, vagina, and intestines. Normally, E. faecalis is a friendly commensal bacterium in the intestines, but it can lead to serious human diseases if it spreads to other human tissues.
Currently, a wide variety of E. faecalis strains or species, have been isolated and identified in different human samples. Infections with E. faecalis can show many symptoms, including but not limited to fever, headache, diarrhea, vomiting, as well as stiff neck, based on specific E. faecalis types. Moreover, pilot studies have demonstrated that the treatment for E. faecalis-based infection diseases can be particularly difficult due to their resistance to many types of antibiotics. In recent years, many reports have revealed that E. faecalis can be used as NGP candidates for preventing or treating certain human and animal diseases.
E. faecalis for Disease Treatment
E. faecalis has been considered as the main type of live biotherapeutics drug in a wide collection of disease therapy. In recent years, a number of E. faecalis-based NGPs have also been generated and used both in pre-clinical trials and clinical trials. As an expert in NGP development, Creative Biolabs has established a panel of assays to develop various types of E. faecalis-based NGPs for human disease therapies.
|
Diseases
|
Functions of E. faecalis
|
|
Parkinson's Disease
|
Parkinson's disease is a type of neurodegenerative disorder that is often caused by the loss of dopaminergic neurons. Symptoms emerge slowly, sometimes beginning with shaking, stiffness, and slowing of movement. Till now, many researchers have indicated that several E. faecalis strains have beneficial health effects in treating patients with Parkinson's disease. For example, the safety and efficacy of E. faecalis strain v583 have been evaluated in 50 patients with Parkinson's disease and 50 healthy controls. The data have suggested that E. faecalis-based NGPs play an important role in reducing pro-inflammatory cytokines and inhibiting the overgrowth of pathogenic bacteria in patients.
|
|
Inflammatory Bowel Disease (IBD)
|
Inflammatory bowel disease (IBD) is an intestinal disorder that can cause chronic inflammation of the digestive tract and the gut. Recently, some E. faecalis strains have been reported as perfect NGP candidates for the IBD treatment through mediating the immune responses. There is a wealth of evidence that E. faecalis can inhibit the development and progression of IBD by regulating immune systems. For instance, the protective role of inactivated E. faecalis strain EF-2001 has been assessed on female NC/Nga mice models. EF-2001 can effectively prevent colonic tissue destruction in mice with IBD.
|
Related Products
|
CAT
|
Product Name
|
Product Overview
|
Price
|
|
LBGF-0722-GF21
|
Enterococcus faecalis
|
E. faecalis is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans. It is found in healthy humans and can be used as a probiotic.
|
Inquiry
|
|
LBGF-0224-GF45
|
Heat inactivated Enterococcus faecalis
|
E. faecalis has been inactivated by heating to 65°C for 30 minutes.
|
Inquiry
|
With the commitment of being your best NGP discovery partner, Creative Biolabs has established the utmost efficient integrated solutions to innovate and accelerate your E. faecalis-based NGP development for various types of diseases. We have won a good reputation among our worldwide customers for accomplishing numerous challenging projects on E. faecalis NGPs. We have experienced experts and advanced platforms that can provide excellent services. If you are interested in our services, please contact us to get more information and a quote for your project details.
Brochures
FAQs
What makes E. faecalis a promising candidate for next-generation probiotics?
E. faecalis is a promising probiotic candidate due to its ability to colonize the gastrointestinal tract effectively and its potential to contribute to gut health by modulating the microbiota. This bacterium has shown beneficial effects in enhancing immune responses, suppressing pathogen growth, and producing antimicrobial substances. Research also highlights its ability to withstand harsh conditions in the gut, which is crucial for probiotic efficacy.
How does E. faecalis interact with the host microbiota?
E. faecalis interacts with the host microbiota by competing with pathogenic microorganisms for resources and space, producing antimicrobial compounds, and stimulating the host's immune responses. It helps maintain a balanced gut ecosystem by supporting beneficial bacteria and suppressing harmful ones. This interaction is crucial for its effectiveness as a probiotic and its role in promoting overall gut health.
What are the key research methodologies for studying E. faecalis as a probiotic?
Key research methodologies for studying E. faecalis as a probiotic include in vitro assays to evaluate its antimicrobial activity, in vivo studies to assess its effects on gut health, and clinical trials to determine its efficacy and safety in humans. Genomic and proteomic analyses can provide insights into its functional properties and mechanisms of action. These methodologies help in understanding its potential benefits and applications as a probiotic.
What are the current challenges in developing E. faecalis-based probiotics?
Current challenges in developing E. faecalis-based probiotics include ensuring strain-specific efficacy, maintaining stability and viability throughout the product's shelf life, and addressing potential safety concerns. Additionally, regulatory approvals and the need for extensive clinical trials can pose significant hurdles. Overcoming these challenges requires ongoing research and development to optimize formulations and validate health claims.
Resources
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
